Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Media

Logo

FDA Accepts Shorla’s NDA for SH-201 to Treat Leukemia and Other Cancers

April 22nd 2024

Read More

Logo

FDA Receives New Drug Application for SH-105 in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Read More

Logo

OncLive/ SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Read More

Logo

Targeted Oncology/ FDA Ok’s NDA for SH-105 in Breast and Ovarian Cancer

January 15th 2024January 15th 2024

Read More

Logo

Pharmaceutical Executive/ FDA Accepts New Drug Application for Shorla Oncology’s Novel Treatment for Breast, Ovarian Cancer

January 29th 2024January 12th 2024

Read More

Logo

Goodman-backed Shorla Oncology secures $35m in Series-B funding

October 24th 2023

Read More

Logo

Shorla Oncology raises $35m to accelerate growth

October 24th 2023

Read More

Photo

Raising Funds in a Tight Market: Q&A With Sharon Cunningham, CEO of Shorla Oncology

October 24th 2023

Read More

Banner

Women Of The Year 2023 Awards Nomination

September 28th 2023

Read More

Older posts
Newer posts
Page1 … Page3 Page4 Page5 … Page7
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.